4. A total of 81 cases of patients with cirrhosis of the liver basis, of which 39 patients received chemoembolization, the median survival was 4.08 months, 42 patients received embolization, the median survival of 3.5 months, The average of TTP, mediansurvival and survival curves difference between two groups of patients has not statistically significant.j Conclusion: TAE was effective and safety for primary hepatocellular carcinoma associated with ascites, leukopenia, and portal vein tumor thrombus, liver cirrhosis. Key Word(s): 1. TACE,; 2. HCC; 3. leukopenia; Presenting

Author: LILI DING Additional Authors: JUNPU GAO, QIJUN NIU Corresponding Author: LILI DING Affiliations: jilin university Objective: The objective of the present study was to explore Raf inhibitor the different metabolic substances in sera between hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV) or hepatitis C virus (HCV). We used the metabonomic method to profiling the sera among liver cirrhosis, see more liver cancer

and normal persons, and find potential tumor biomarkers. Methods: UPLC/Q-TOF-MS was utilized to profile the different metabolic substances in sera among 29 cases of liver cirrhosis which induced by HBV and HCV respectively, 38 and 32 cases of HCC sera which induced by HBV and HCV respectively, and

30 cases of normal persons. We got retention time, m/z and total electrories MCE strength related figure, then matched peaks, normalized these peaks, and analysed the data with PCA and PLS methods, matched these substances with human metabonomics database, the different substances between each team may be the potential biomarkers. Results: Metabolic substances in liver cirrhosis caused by HBV and HCV had no differences. Twenty-six substances were identified as potential tumor markers, ten compounds were identified as: LysoPC (20 : 1), LysoPC (20 : 2), LysoPC (P-18 : 0), LysoPC (P-18 : 0), LysoPC (15 : 0), arachidonic acid, hemolysis phosphatidyl choline, carnitine, glycine, tryptophan, N-Arachidonoyl glycine. Conclusion: There were no differences between liver cirrhosis between HBV and HCV induced liver cancer in metabolites level. Through analysising liver cirrhosis and liver cancer sera, Twenty-six different substances were found, LysoPC (20 : 1), LysoPC (20 : 2), LysoPC (P-18 : 0), LysoPC (P-18 : 0), LysoPC (15 : 0), arachidonic acid, hemolysis phosphatidyl choline, carnitine (C18 : 1), carnitine (C18 : 2), glycine, tryptophan, N-Arachidonoyl glycine, they are the potential tumor biomarkers of HCC. Key Word(s): 1. Metabonomics; 2. HCC; 3. liver cirrhosis; 4.